Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the target of a significant drop in short interest during the month of January. As of January 12th, there was short interest totalling 1,594,647 shares, a drop of 17.1% from the December 29th total of 1,923,990 shares. Based on an average trading volume of 569,101 shares, the days-to-cover ratio is presently 2.8 days. Approximately 2.1% of the shares of the stock are sold short.
ATNM has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. Maxim Group restated a “buy” rating and issued a $3.00 target price on shares of Actinium Pharmaceuticals in a research report on Wednesday, October 25th. Roth Capital restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Finally, B. Riley initiated coverage on shares of Actinium Pharmaceuticals in a research report on Wednesday, December 6th. They issued a “buy” rating and a $2.75 target price on the stock. Five research analysts have rated the stock with a buy rating, Actinium Pharmaceuticals presently has an average rating of “Buy” and an average target price of $3.75.
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.74 on Thursday. The company has a market cap of $59.14, a price-to-earnings ratio of -1.57 and a beta of 41.30. Actinium Pharmaceuticals has a fifty-two week low of $0.54 and a fifty-two week high of $1.72.
WARNING: “Actinium Pharmaceuticals Inc (ATNM) Short Interest Update” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/25/actinium-pharmaceuticals-inc-atnm-short-interest-update-3.html.
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.